| Description |
1 online resource (xvii, 152 pages) : illustrations |
| Contents |
Introduction -- Logistics, supply, and demand -- Financing of MD TB SLDs -- Innovative suggestions and potential solutions |
| Summary |
To effectively treat patients diagnosed with drug-resistant (DR) tuberculosis (TB) and protect the population from further transmission of this infectious disease, an uninterrupted supply of quality-assured (QA), second-line anti-TB drugs (SLDs) is necessary. Patients diagnosed with multidrug-resistant tuberculosis (MDR TB)--a disease caused by strains of Mycobacterium tuberculosis (M.tb.) resistant to two primary TB drugs (isoniazid and rifampicin)--face lengthy treatment regimens of 2 years or more with daily, directly observed treatment (DOT) with SLDs that are less potent, more toxic, and more expensive than those used to treat drug-susceptible TB. From 2000 to 2009, only 0.2-0.5 percent of the estimated 5 million MDR TB cases globally were treated with drugs of known quality and in programs capable of delivering appropriate care (Keshavjee, 2012). The vast majority of MDR TB patients either died from lack of treatment or contributed to the spread of MDR TB in their communities. A strengthened global supply chain for SLDs could save lives by consistently delivering high-quality medicines to more of the people who need them |
| Notes |
Title from PDF title page |
| Bibliography |
Includes bibliographical references |
| Notes |
This activity was supported by contracts between the National Academy of Sciences and Department of Health and Human Services (Contract Nos. N01-OD-4-2139 and HHSF223001003T), Abbott Pharmaceuticals, American Diabetes Association, American Society for Microbiology, Amgen Inc., Association of American Medical Colleges, Bristol-Myers Squibb, Burroughs Wellcome Fund, Celtic Therapeutics, LLLP, Critical Path Institute, Doris Duke Charitable Foundation, Eli Lilly and Company, Eli Lilly & Co. Foundation, FasterCures, Foundation for the NIH, Friends of Cancer Research, GlaxoSmithKline, Janssen Research & Development, LLC, March of Dimes Foundation, Merck & Co., Inc., Novartis Pharmaceuticals Corporation, and Pfizer Inc |
|
Version viewed: Oct. 26, 2013 |
| Subject |
Multidrug-resistant tuberculosis -- Prevention -- Congresses
|
|
Business logistics -- Congresses
|
|
International cooperation -- Congresses
|
|
Tuberculosis, Multidrug-Resistant -- drug therapy
|
|
Extensively Drug-Resistant Tuberculosis -- drug therapy
|
|
Internationality
|
|
POLITICAL SCIENCE -- Public Policy -- Social Security.
|
|
POLITICAL SCIENCE -- Public Policy -- Social Services & Welfare.
|
|
Business logistics
|
|
International cooperation
|
| Genre/Form |
proceedings (reports)
|
|
Conference papers and proceedings
|
|
Conference papers and proceedings.
|
|
Actes de congrès.
|
| Form |
Electronic book
|
| Author |
English, Rebecca A., author.
|
|
Guenther, Rita S., author.
|
|
Claiborne, Anne B., author.
|
|
Institute of Medicine (U.S.). Forum on Drug Discovery, Development, and Translation, sponsoring body.
|
|
Workshop on Global Drug Supply Chain for Secondline Anti-tuberculosis Drugs (2012 : Washington, D.C.)
|
| ISBN |
9780309265980 |
|
0309265983 |
|
9780309265966 |
|
0309265967 |
|
